1. Home
  2. EPOW vs AYTU Comparison

EPOW vs AYTU Comparison

Compare EPOW & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.77

Market Cap

29.9M

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

N/A

Current Price

$2.55

Market Cap

25.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPOW
AYTU
Founded
2014
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
25.7M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
EPOW
AYTU
Price
$0.77
$2.55
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
55.3K
33.6K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.66
$1.07
52 Week High
$1.86
$3.07

Technical Indicators

Market Signals
Indicator
EPOW
AYTU
Relative Strength Index (RSI) 45.83 46.72
Support Level $0.66 $2.46
Resistance Level $1.04 $2.66
Average True Range (ATR) 0.06 0.11
MACD -0.00 -0.01
Stochastic Oscillator 9.95 36.44

Price Performance

Historical Comparison
EPOW
AYTU

About EPOW Sunrise New Energy Co. Ltd

E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: